RECURRENT HEPATOCELLULAR CARCINOMA
Clinical trials for RECURRENT HEPATOCELLULAR CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HEPATOCELLULAR CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT HEPATOCELLULAR CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Proton beam vs X-Ray: which radiation is better for liver cancer?
Disease control OngoingThis study compares two types of radiation therapy for people with liver cancer that cannot be removed by surgery or has come back. One type uses standard X-rays (photons), while the other uses proton beams, which may cause less harm to healthy organs nearby. The goal is to see i…
Matched conditions: RECURRENT HEPATOCELLULAR CARCINOMA
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 17, 2026 00:59 UTC
-
New drug combo aims to boost immune attack on tough liver cancers
Disease control OngoingThis early-phase trial tested a combination of two drugs (IRX-2 and nivolumab) plus a low dose of chemotherapy in 8 adults with advanced liver cancer that had returned or spread. The goal was to find the best dose and check for side effects. The approach aims to help the immune s…
Matched conditions: RECURRENT HEPATOCELLULAR CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 00:52 UTC
-
New hope for kids with rare cancers: drug blocks tumor growth
Disease control OngoingThis study tests a drug called cabozantinib in children and young adults (up to age 30) with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to standard therapy. The drug works by blocking enzymes that help tumors grow and form blood vesse…
Matched conditions: RECURRENT HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:58 UTC
-
Engineered immune cells take on tough liver cancer in early trial
Disease control TerminatedThis early-phase study tests a new treatment for adults with advanced liver cancer that has not responded to at least two standard therapies. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells that have a specific p…
Matched conditions: RECURRENT HEPATOCELLULAR CARCINOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New drug combo targets tough cancers: hope for liver, pancreas, and bile duct tumors
Disease control OngoingThis early-phase study tests a combination of two drugs, guadecitabine and durvalumab, in people with advanced liver, pancreatic, bile duct, or gallbladder cancer that has spread. The main goals are to find the safest dose and see if the drugs can shrink tumors. About 55 particip…
Matched conditions: RECURRENT HEPATOCELLULAR CARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: RECURRENT HEPATOCELLULAR CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC